Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,326,344
  • Shares Outstanding, K 1,035,819
  • Annual Sales, $ 24,556 M
  • Annual Income, $ 3,232 M
  • 60-Month Beta 0.33
  • Price/Sales 4.91
  • Price/Cash Flow 16.78
  • Price/Book 11.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.21
  • Number of Estimates 3
  • High Estimate 1.38
  • Low Estimate 0.90
  • Prior Year 1.34
  • Growth Rate Est. (year over year) -9.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.14 +0.93%
on 04/18/19
132.13 -12.81%
on 03/26/19
-10.04 (-8.02%)
since 03/18/19
3-Month
113.54 +1.46%
on 01/28/19
132.13 -12.81%
on 03/26/19
-1.39 (-1.19%)
since 01/18/19
52-Week
77.09 +49.44%
on 05/04/18
132.13 -12.81%
on 03/26/19
+35.48 (+44.51%)
since 04/18/18

Most Recent Stories

More News
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare...

LLY : 115.20 (-1.12%)
PFE : 39.38 (-1.25%)
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

NVO : 48.39 (-0.25%)
MRK : 73.19 (-0.99%)
LLY : 115.20 (-1.12%)
GILD : 62.95 (-0.47%)
Next Support Level for Eli Lilly & Co (LLY) is $117.08

Shares of Eli Lilly & Co (NYSE:LLY) have bearishly opened below the pivot of $121.39 today and have reached the first support level of $118.51. Analysts will be watching for a cross of the next downside...

LLY : 115.20 (-1.12%)
Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales

Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.

RDUS : 21.43 (-3.47%)
LLY : 115.20 (-1.12%)
NVS : 76.41 (-1.15%)
AMGN : 177.47 (-2.74%)
SmarTrend Watching for Potential Rebound in Shares of Eli Lilly & Co After 1.06% Loss

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $122.76 to a high of $124.26. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $123.02...

LLY : 115.20 (-1.12%)
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer

FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months

JNJ : 137.52 (-0.72%)
MRK : 73.19 (-0.99%)
LLY : 115.20 (-1.12%)
PFE : 39.38 (-1.25%)
Eli Lilly & Co Has Returned % Since SmarTrend Recommendation (LLY)

SmarTrend identified a Downtrend for Eli Lilly & Co (NYSE:LLY) on January 8th, 2019 at $115.47. In approximately 3 months, Eli Lilly & Co has returned 8.31% as of today's recent price of $125.06.

LLY : 115.20 (-1.12%)
Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

BBP : 41.17 (-0.32%)
SBIO : 33.66 (+0.18%)
ARKG : 32.12 (+0.44%)
ONCE : 110.62 (-0.08%)
ILMN : 319.03 (+0.11%)
JNJ : 137.52 (-0.72%)
LLY : 115.20 (-1.12%)
NVS : 76.41 (-1.15%)
RHHBY : 32.6900 (-0.09%)
PFE : 39.38 (-1.25%)
XBI : 84.63 (-0.24%)
BTEC : 32.08 (-0.56%)
Eli Lilly & Co Falls 1.64% on Heavy Volume: Watch For Potential Rebound

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $125.11 to a high of $126.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $126.09...

LLY : 115.20 (-1.12%)
Watch for Eli Lilly & Co to Potentially Rebound After Falling 1.64% Yesterday

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $125.11 to a high of $126.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $126.09...

LLY : 115.20 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 117.84
1st Resistance Point 116.52
Last Price 115.20
1st Support Level 114.01
2nd Support Level 112.81

See More

52-Week High 132.13
Last Price 115.20
Fibonacci 61.8% 111.10
Fibonacci 50% 104.61
Fibonacci 38.2% 98.12
52-Week Low 77.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar